Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With
Untreated Chronic Lymphocytic Leukemia
How well is ibrutinib and obinutuzumab with or without venetoclax work in treating
older patients with untreated chronic lymphocytic leukemia?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax
work in treating older patients with untreated chronic lymphocytic leukemia. Ibrutinib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Immunotherapy with obinutuzumab, may induce changes in body's immune system
and may interfere with the ability of cancer cells to grow and spread. Drugs used
in chemotherapy, such as venetoclax work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving ibrutinib and obinutuzumab with venetoclax may work better
at treating chronic lymphocytic leukemia compared to ibrutinib and obinutuzumab.
Study Reference #: CLYM19014
Lead Researcher (Principal Investigator)
Lead Researcher: Paul Barr
Study Contact InformationStudy Coordinator: Delaney Dretto
Phone: (585) 275-5825
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search